Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

Lingzhi Hong,Seyedeh Dibaj,Marcelo Vailati Negrao,Alexandre Reuben,Emily Roarty,Waree Rinsurongkawong,Jeff Lewis,Don L. Gibbons,Boris Sepesi,Vassiliki A. Papadimitrakopoulou,Bonnie S. Glisson,George R. Blumenschein,P.A. Futreal,Ignacio I. Wistuba,Jack A. Roth,Stephen G. Swisher,John V. Heymach,George R. Simon,J. Jack Lee,Jianjun Zhang

Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

2019

9017Background: Temporal and spatial heterogeneity of PD-L1 has been reported. However, its impact on clinical benefit from immune checkpoint inhibitor (ICI) has not been clearly defined. Methods: ...

Keywords:

PD-L1
Blockade
Cancer research
non-small cell lung cancer (NSCLC)
Pathology
Immune checkpoint
Medicine
temporal heterogeneity
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations